Madera BioSciences, Inc.
First effective Alzheimer's drug will be an costly antibody. Madera is the small molecule alternative for cost-effective long-term therapy.
Madera BioSciences is a startup biotechnology company founded by Edwin Iwanowicz, Ph.D. in 2008. The company provides innovative small molecule experimental therapeutics for the treatment of Alzheimer’s disease to pharma companies. Madera’s technology niche is to clear a key pathogen protein, amyloid beta. Our intellectual property resulted from a successful collaboration with Eli Lilly. The company have raised > $640K and seeks $2M.